GA

Gururaj Ananda Rao

Active Director Managing Director DIN 01902753
DIN 01902753 First appointment Jan 2000 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Past companies 2 historical roles
Total affiliations 5 Since Jan 2000
Shareholding value •••• Premium profile

About Gururaj Ananda Rao

Data last updated:

Gururaj Ananda Rao is a Managing Director at Icrest Biotechnologies Limited (since 2010), Director at Sri Raghavendra Biotechnologies Private Limited (since 2000) and Designated Partner at Atoz Biotech Academy Llp (since 2022). The companies operate in Healthcare and Life Sciences. The 2 current companies with reported revenue have a combined latest revenue of ₹1.73 Cr; the largest is Icrest Biotechnologies Limited at ₹1.68 Cr (FY 2025). Earlier, Gururaj Ananda Rao was a Director at Cryo Stemcell Private Limited (2010) and Nominee Director at Cellf Therapeutics Private Limited (2020–2021).

DIN 01902753
Primary Designation Managing Director
Industry Healthcare
First Appointment 27 Jan 2000
Oldest Company Age 26 yrs
Largest company Icrest Biotechnologies Limited · ₹1.68 Cr (FY 2025)
Combined revenue ₹1.73 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Icrest Biotechnologies Limited U33100KA2008PLC047800
Managing Director01 Dec 20102008₹1.68 Cr (FY 2025)Active
Director27 Jan 20002000₹5 Lakh (FY 2025)Active
Designated Partner17 Feb 20222022Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Cryo Stemcell Private Limited U85195KA2003PTC031964
Director08 Jan 20102003₹1.11 Cr (FY 2018)Strike Off
Cellf Therapeutics Private Limited U73100KA2020PTC134938
Nominee Director16 Jun 20202020₹6.1 Lakh (FY 2024)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Atoz Biotech Academy Llp
Icrest Biotechnologies Limited
Sri Raghavendra Biotechnologies Private Limited
Cryo Stemcell Private Limited
Premium access

Shareholding and investment profile for Gururaj Ananda Rao

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gururaj Ananda Rao

Gururaj Ananda Rao currently holds 3 directorships: Icrest Biotechnologies Limited (Managing Director, since 01 Dec 2010, revenue ₹1.68 Cr (FY 2025)); Sri Raghavendra Biotechnologies Private Limited (Director, since 27 Jan 2000, revenue ₹5 Lakh (FY 2025)); Atoz Biotech Academy Llp (Designated Partner, since 17 Feb 2022).

Gururaj Ananda Rao was first appointed on 27 Jan 2000 as Director at Sri Raghavendra Biotechnologies Private Limited. The most recent appointment on record is 17 Feb 2022 at Atoz Biotech Academy Llp.

The 2 current companies of Gururaj Ananda Rao that report revenue have a combined latest revenue of ₹1.73 Cr: Icrest Biotechnologies Limited ₹1.68 Cr (FY 2025); Sri Raghavendra Biotechnologies Private Limited ₹5 Lakh (FY 2025).

Gururaj Ananda Rao held 2 earlier board appointments: Cryo Stemcell Private Limited (Director, 08 Jan 2010 to 06 Mar 2010); Cellf Therapeutics Private Limited (Nominee Director, 16 Jun 2020 to 24 Mar 2021).

The current boards of Gururaj Ananda Rao's companies include Basavalinga Ajaikumar Sadasivaiah (Icrest Biotechnologies Limited), Gopalakrishna Sreemushanam Anandarao (Icrest Biotechnologies Limited), Jyothsna Ananda Rao (Icrest Biotechnologies Limited), Sunanda Ananda Rao (Icrest Biotechnologies Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available